The common agents of endocrine therapy including aromatase inhibitors (AIs) and Tamoxifen have significantly improved outcomes for postmenopausal female patients who suffered from breast cancer (BC) [3], endometrial cancer (EC) [4], and ovarian cancer (OC) [5]. Here, CYP19A1 is linked to breast cancer.